▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1817 by analyst upside · 2026-06-27
PRCT
PROCEPT BioRobotics Corporation
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+33.9%
implied upside to consensus target
Current Price $22.56
Consensus Target $30.2
Bull Target $37.0
Bear Target $20.0
Analysts Covering 10
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
5
Hold
3
Sell
1
52-Week Low $19.35
52-Week High $62.17
YTD Return -26.7%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E -25.9x
EPS (TTM) $-1.83
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $322M
Profit Margin -31.8%
52-WEEK RANGE
52-Week Low $19.35
52-Week High $62.17
Current Price $22.56
Bear Target $20.0
Bull Target $37.0
● Now $22.56 ● Target $30.2
TRADING DATA
Avg Volume 1.5M
YTD Return -26.7%
Analyst Count 10
Consensus Buy
Upside to Target +33.9%
Last Updated 2026-06-27

ANALYST SUMMARY

PROCEPT BioRobotics Corporation (PRCT) is currently trading at $22.56 with a Wall Street consensus price target of $30.2, implying potential upside of 33.9% over the next 12 months. 10 analysts currently cover PRCT, with a consensus rating of Buy — 60% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $37.0, while the most cautious has a target of $20.0.

PRCT operates in the Healthcare sector with a market capitalisation of $1B. The stock is down 26.7% year-to-date and is currently trading near the lower end of its 52-week range of $19.35 – $62.17.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ARDT +27.5%
Ardent Health, Inc.
$1B · P/E 10.4x · Buy
PAHC +43.9%
Phibro Animal Health Corporation
$1B · P/E 13.7x · Hold
NUTX +41.5%
Nutex Health Inc.
$1B · P/E 12.2x · Buy
COLL +48.5%
Collegium Pharmaceutical, Inc.
$1B · P/E 17.8x · Buy
INSP +11.4%
Inspire Medical Systems, Inc.
$1B · P/E 9.9x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for PRCT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners ↓ Downgrade
Outperform → Market Perform 2026-06-11 29% win rate (7 calls)
Piper Sandler reit
Overweight → Overweight 2026-04-30 14% win rate (7 calls)
Baird ● Initiated
Neutral 2026-03-06 Building track record
Truist Securities — Reiterated
Buy → Buy 2026-03-02 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2026-02-26 29% win rate (7 calls)
TD Cowen — Reiterated
Buy → Buy 2026-02-26 Building track record
Oppenheimer ↓ Downgrade
Outperform → Perform 2026-02-26 14% win rate (7 calls)
Piper Sandler — Reiterated
Overweight → Overweight 2026-02-26 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →